Moleculin Biotech presents interim Phase 3 data for Annamycin, reporting 39% complete response and 54% complete response rate in pooled arms.

Observed price moves

• MBRX+2.77%15 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next. We pay about $120,000 a month for the newswires behind this feed.